PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients

	Tweet

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

PSA levels in a prostate cancer patient are monitored after a patient’s treatments, and after a successful course of EBRT the levels should decline gradually over the following 18 to 24 months. A continued rise in PSA can indicate relapsing disease.

Prior studies have attempted to categorize PSA response patterns after treatment in an effort to identify patients with an increased chance of a relapse earlier; however, most did not use a fixed point after treatment to predict outcomes. 

Researchers at the Memorial Sloan-Kettering Cancer Center department of Radiation Oncology and Epidemiology and Biostatistics in New York, sought to determine the significance of a patient’s reaching a certain PSA level at a specific point in time after EBRT.

The study authors found that patients with a PSA value of less than or equal to 1.5 at two years had a 2.4 percent incidence of distant metastases at five years after treatment and a 7.9 percent incidence at 10 years after treatment. Patients with a PSA value higher than 1.5 experienced a significantly higher rate of metastases at five and 10 years after treatment (10 percent and 17.5 percent, respectively).

“In the past, patients with a relapsing cancer after receiving radiation were not identified until several years after treatment and at that point it may be too late to effectively salvage their recurrence,” Michael Zelefsky, M.D., lead author of the study and a radiation oncologist at Memorial Sloan-Kettering Cancer Center, said. “If we can catch these future instances of cancer recurrence earlier in prostate cancer patients, then we have a much higher chance of reducing the mortality associated with the cancer.”

###

ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. For more information on radiation therapy, visit http://www.rtanswers.org. To learn more about ASTRO, visit http://www.astro.org.

Contact: Beth Bukata

703-839-7332
American Society for Radiation Oncology

RELATED STORIES:
Excessive Multivitamin Use May Raise Risk for Prostate Cancer   Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians   Too many old men get prostate cancer tests: study   Delay OK before radiation for prostate cancer   Does race, income predict prostate cancer outcome?   Accurate Prostate Cancer Diagnosis Depends on Biopsy Location   deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer   New Treatment for Advanced Prostate Cancer   Prostate cancer patients are at increased risk of precancerous colon polyps   Gonorrhea linked to higher prostate cancer risk   Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear   Predictive model of prostate cancer risk   Possible link found between x-rays and prostate cancer   Online tool supports more dialogue on prostate cancer risk   Change in PSA level does not predict prostate cancer   Brisk walking may help men with prostate cancer, UCSF study finds   Few Side Effects from Radiation Treatment Given After Prostate Cancer Surgery   Higher vitamin K intake tied to lower cancer risks   Prostate Cancer Etiology   Discovery of a new virus in prostate tumors   Prostate Cancer Differential Diagnosis   Researchers Uncover How Prostate Cancer Cells Defy Death

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]